Rxivist logo

CHASMplus reveals the scope of somatic missense mutations driving human cancers

By Collin Tokheim, Rachel Karchin

Posted 02 May 2018
bioRxiv DOI: 10.1101/313296 (published DOI: 10.1016/j.cels.2019.05.005)

Large-scale cancer sequencing studies of patient cohorts have statistically implicated many genes driving cancer growth and progression, and their identification has yielded substantial translational impact. However, a remaining challenge is to increase the resolution of driver prediction from the gene level to the mutation level, because mutation-level predictions are more closely aligned with the goal of precision cancer medicine. Here we present CHASMplus, a computational method, that is uniquely capable of identifying driver missense mutations, including those specific to a cancer type, as evidenced by significantly superior performance on diverse benchmarks. Applied to 8,657 tumor samples across 32 cancer types in The Cancer Genome Atlas, CHASMplus identifies over 4,000 unique driver missense mutations in 240 genes, supporting a prominent role for rare driver mutations. We show which TCGA cancer types are likely to yield discovery of new driver missense mutations by additional sequencing, which has important implications for public policy.

Download data

  • Downloaded 1,461 times
  • Download rankings, all-time:
    • Site-wide: 16,856
    • In bioinformatics: 1,866
  • Year to date:
    • Site-wide: 105,937
  • Since beginning of last month:
    • Site-wide: 51,551

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide